A broad licensing and research alliance will hand Sarepta four clinical-stage candidates, while Arrowhead receives $500 ...

Strategic Sarepta partnership and FDA filing position Arrowhead for a transformative leap in RNAi therapeutics ...

H.C. Wainwright has recently initiated Sarepta Therapeutics Inc (SRPT) stock to Sell rating, as announced on November 25, 2024, according to Finviz. Earlier, on November 7, 2024, Cantor Fitzgerald had ...